Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib

Abstract

Erlotinib is a novel oral tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR). Skin reactions are a frequent side-effect of erlotinib therapy with various clinical manifestations such as papulo-pustular rash, xerosis, paronychia and hair changes [1]. We report two patients with advanced solid tumors who were diagnosed with a histologically confirmed cutaneous leukocytoclastic vasculitis occurring during treatment with erlotinib.